The current therapeutic approach for anaemia after kidney transplant
We present relevant studies of HIF-PHi in the transplant population and its implications on the management of posttransplant anaemia.
Recent findings
Data on HIF-PHi use in the kidney transplant population are promising. Limited data demonstrate a significant increase in haemoglobin, with a comparable safety profile to epoetin. Reported adverse effects include overcorrection and low iron stores.
Summary
Current therapeutic approaches to anaemia in the kidney transplant population is mostly derived from the CKD population. More studies are needed on HIF-Phi, a novel class of ESAs that has thus far demonstrated promise in the kidney transplant population.
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: NOVEL THERAPEUTIC APPROACHES IN NEPHROLOGY AND HYPERTENSION: Edited by Ekamol Tantisattamo, Ramy M. Hanna and Kamyar Kalantar-Zadeh Source Type: research
More News: Anemia | Chronic Kidney Disease | Hypertension | Iron | Kidney Transplant | Kidney Transplantation | Study | Transplant Surgery | Transplants | Urology & Nephrology